News – Overland Park Peptides (ARL)

FDA approval Aug 07, 2026 Retatrutide vs. Tirzepatide for Obesity Decline: Addressing GLP-1 Misuse Risks Highlighted by DoctorsRetatrutide and tirzepatide are two peptides studied for obesity, but only tirzepatide is FDA-approved. Doctors warn about misuse risks of...Read article

alcohol use disorder Aug 05, 2026 Retatrutide in VA Alcohol Use Disorder Trials: Could the Triple-Agonist Outperform Tirzepatide for Veterans?The VA is testing retatrutide, a triple-agonist peptide, for alcohol use disorder. Could it outperform tirzepatide? This article examines the...Read article

FDA warning retatrutide Jul 31, 2026 Retatrutide Compounding Risks After FDA WarningRetatrutide compounding faces FDA scrutiny over stability risks. This article compares the triple-agonist's stability to tirzepatide and semaglutideRead article

compounding Jul 29, 2026 Retatrutide and the FDA Peptide Panel Vote: Could Triple-Agonist Compounding Outlast Tirzepatide Shortages?The FDA's peptide panel vote could reshape compounding access for retatrutide, a triple-agonist still in trials. As tirzepatide shortages persist,...Read article

GLP-1 agonists Jul 24, 2026 Retatrutide for Post-Ramadan Weight RegainRetatrutide, an investigational triple agonist, may help mitigate semaglutide resumption intolerance after Ramadan. This article examines the regulatoryRead article

GIP Jul 22, 2026 Tirzepatide vs. Retatrutide for Menstrual Cycle ChangesTirzepatide and retatrutide are incretin-based therapies with different receptor targets. This article examines their potential effects on menstrual cyclesRead article